1h Free Analyst Time
The diffuse large b-cell lymphoma (DLBCL) therapeutics market is forecast to grow by USD 2.24 billion during 2023-2028, accelerating at a CAGR of 8.09% during the forecast period. The report on the diffuse large b-cell lymphoma (DLBCL) therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing geriatric population, increasing incidence of DLBCL, and increasing approval of therapeutics for patients with relapsed or refractory DLBCL.
The diffuse large b-cell lymphoma (DLBCL) therapeutics market is segmented as below:
By Application
- Hospital pharmacy
- Retail pharmacy
- Online pharmacy
- Others
By Product
- Small molecules
- Biologics
By Geography
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the diffuse large b-cell lymphoma (DLBCL) therapeutics market covers the following areas:
- Diffuse large b-cell lymphoma (DLBCL) therapeutics market sizing
- Diffuse large b-cell lymphoma (DLBCL) therapeutics market forecast
- Diffuse large b-cell lymphoma (DLBCL) therapeutics market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Application
7 Market Segmentation by Product
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global diffuse large b-cell lymphoma (DLBCL) therapeutics market: AbbVie Inc., ADC Therapeutics SA, Amgen Inc., Bayer AG, BeiGene Ltd., Bristol Myers Squibb Co., Celltrion Healthcare Co. Ltd., CTI BioPharma Corp., Erytech Pharma SA, F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Merck and Co. Inc., Novartis AG, Pfizer Inc., Seagen Inc., Spectrum Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is technological advances."
According to the report, one of the major drivers for this market is the growing geriatric population.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- ADC Therapeutics SA
- Amgen Inc.
- Bayer AG
- BeiGene Ltd.
- Bristol Myers Squibb Co.
- Celltrion Healthcare Co. Ltd.
- CTI BioPharma Corp.
- Erytech Pharma SA
- F. Hoffmann La Roche Ltd.
- Gilead Sciences Inc.
- GlaxoSmithKline Plc
- Johnson and Johnson Services Inc.
- Merck and Co. Inc.
- Novartis AG
- Pfizer Inc.
- Seagen Inc.
- Spectrum Pharmaceuticals Inc.
- Takeda Pharmaceutical Co. Ltd.
- Teva Pharmaceutical Industries Ltd.
